BACKGROUND Sustained sympathetic activation contributes to the progression of myocardial cell injury, cardiac
Alternative interventional therapeutic approaches are under development to replace or supplement contemporary pharmacologic strategies for the treatment of HF (9) . Renal denervation (RDN) is a minimally invasive endovascular procedure whereby radiofrequency (RF) energy is used to ablate the sympathetic nerves that traverse the renal artery (10) 
Numerous clinical trials in HF patients
report that beta-blockers augment cardioprotective and vasculoprotective circulating natriuretic peptide (NP) levels by some unidentified mechanism(s) (14) (15) (16) (17) (18) (19) . Beta 1 -adrenergic receptors are located in the kidneys and are innervated by renal sympathetic nerves. Therefore, we propose that in HF, elevated renal nerve activity opposes the beneficial renal, vascular, and cardiac protective effects of NP by a pathway involving enhanced metabolism of NP.
Therefore, the aim of these investigations was to test the efficacy of RF-RDN as a treatment of HF and to determine the effects of this procedure on the synthesis and metabolism of NP. For these studies, changes in cardiac and vascular function and NP levels produced by bilateral RF-RDN were examined in spontaneously hypertensive rats (SHR) or normotensive Wistar-Kyoto (WKY) rats with HF.
METHODS
Male SHR and male WKY 19 to 20 weeks of age (Charles River Laboratories, Wilmington, Massachusetts) were used in the study (Online Appendix).
Myocardial ischemia reperfusion was performed as previously described (19) . Following 45 min of ischemia, rats were reperfused for 12 weeks and assessed for cardiac remodeling and failure. The experimental protocol is described in Figure 1 .
SHR and WKY were randomized into either a RF-RDN or sham-RDN group 4 weeks after ischemia reperfusion using 2-h plasma cardiac troponin I concentrations to ensure equal initial cardiac injury and myocardial cell death between groups. RF-RDN was performed as previously described (19, 20) .
Additional SHR (n ¼ 4 to 5 per group) and WKY (n ¼ 7 per group) at 19 weeks of age were implanted with a radio telemetry transmitter (Data Sciences International, St. Paul, Minnesota) for measurement of blood pressure and heart rate as previously described (19) . PLASMA NOREPINEPHRINE MEASUREMENT. At the 12-week endpoint, plasma was collected and catecholamine levels were measured using enzymelinked immunosorbent assay technique according to the manufacturer's recommendations (Abnova Corp., Taipei, Taiwan).
PLASMA RENIN MEASUREMENT, ANGIOTENSIN II
MEASUREMENT. See the Online Appendix.
TYROSINE HYDROXYLASE STAINING OF RENAL
ARTERIES. At 8 weeks following sham-RDN or RF-RDN (12 weeks after reperfusion), renal arteries distal to the RF lesion were excised, fixed, sectioned, stained, and scored as previously described (19) .
MYOCARDIAL NITRITE LEVELS.
Nitrite concentrations were quantified as previously described (21) using an automated ion chromatography system (ENO30 Analyzer, Eicom, San Diego, California).
RIBONUCLEIC ACID ISOLATION AND REVERSE
TRANSCRIPTASE REAL-TIME POLYMERASE CHAIN REACTION, NATRIURETIC PEPTIDE QUANTIFICATION. See the Online Appendix.
NEPRILYSIN ACTIVITY ASSAY. Neprilysin enzyme activity was determined as previously described (22) (Online Appendix).
MYOCARDIAL FIBROSIS. Hearts were collected at the 12-week endpoint, tissues were paraffin embedded and stained with either Masson trichrome or picrosirius red (Online Appendix).
EX VIVO AORTIC VASCULAR REACTIVITY EXPERIMENTS.
See the Online Appendix.
BISOPROLOL PREPARATION AND ADMINISTRATION.
WKY rats received 1 mg/kg/day bisoprolol in the drinking water. This dose was selected based on previous rat studies to ensure cardiac improvements and heart rate reduction (23) . Prior to administration, drinking studies were performed to calculate Polhemus et al.
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Renal Sympathetic Denervation Protects the Failing Heart O C T O B E R 2 4 , 2 0 1 7 : 2 1 3 9 -5 3 (Online Figure 1A) . RF-RDN did not significantly alter circulating substance P levels ( Figure Figure 1 .
Polhemus et al.
Renal Sympathetic Denervation Protects the Failing Heart (Online Figures 4C and 4D ). These results suggest that the cardioprotective effects of RF-RDN extend beyond inactivation of the RAS system. Polhemus et al. Bars ¼ 50 mm (A, left and left center) and 100 mm (A, right center and right). Abbreviations as in Figures 1, 3 , and 4.
Renal Sympathetic Denervation Protects the Failing Heart significantly enhance the release of NP from the cardiac myocyte (Online Figure 5E) . As in the setting of hypertension, RF-RDN significantly inhibited renal neprilysin activity during HF ( Figure 7F) . Likewise, RF-RDN significantly increased circulating bradykinin levels following RF-RDN in WKY in the setting of HF (Online Figure 5F ). Figures 1, 3, 4 , and 7.
P.O. ¼ orally; other abbreviations as in
Polhemus et al. Renal Sympathetic Denervation Protects the Failing Heart total neprilysin protein levels were unchanged, the inhibition of activity was likely due to a posttranslation modification of the protein.
In the 1980s, the heart was first recognized as an endocrine organ that secretes a family of hormones called NP (26) . These peptides were originally shown to act on the vasculature and kidney to produce natriuresis, diuresis, and peripheral vasodilation to compensate for increased cardiac wall stress and volume (27) . Ventricular dilation and myocyte stretch triggers the synthesis and release of NP, and therefore, circulating BNP levels are an established biomarker of HF severity (28) (29) (30) . In addition to their ability to clear sodium and water and relax smooth muscle, NP act directly on the heart and elicit Renal Sympathetic Denervation Protects the Failing Heart O C T O B E R 2 4 , 2 0 1 7 : 2 1 3 9 -5 3 growth factor, and metallopeptidase inhibitor 3), myofibroblast conversion, proliferation, and inflammation (COX2, interleukin 6, and tumor necrosis factor alpha) (37) . In the current study we similarly observed reductions in gene transcription levels of transforming growth factor beta, collagen types 1 and 3, connective tissue growth factor, and interleukin 6 following RF-RDN therapy. Overall, we found that RF-RDN treatment reduced ventricular fibrosis, minimized infarct expansion, and improved LV function.
In the current study we also found that NP levels were elevated and renal neprilysin activity was inhibited in rats treated with the beta 1 In a previous study, we reported that RF-RDN improves endothelial NO synthase function and reduces oxidative stress in the setting of hypertension (19) . 
Renal Sympathetic Denervation Protects the Failing Heart pressure reductions were maintained up to 3-year follow-up (43) . As the field remains in its infancy, we do not have long-term data to substantiate permanent denervation of the renal nerves. 
CONCLUSIONS
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